Ridgefield-based Boehringer Ingelheim can now offer a new treatment to people suffering from a lung condition.
The company announced the U.S. Food and Drug Administration approved its inhalation spray, Stiolto Respimat, as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD.
COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease, according to a statement from the company. More than 15 million Americans have been told that they have the disease, but as many as 45 percent of the total estimated COPD cases in the U.S. remain undiagnosed, Boehringer Ingelheim said. COPD symptoms can negatively impact a patient”™s ability to breathe, especially when performing daily activities.
